Fig. 4
Insufficient inhibition of let-7-deficienct bMSC med on endothelial glycocalyx (EG) degradation and leakage. A Heat map of the top 20 miRNA co-expressed in bMSC-EVs (n = 3). B Transendothelial resistance value to baseline (0 h) in human umbilical vein endothelial cells (HUVECs) treated with normal bMSC med and let-7-deficient bMSC med. X-axis: time (h), (n = 3). C Western blot images and quantitative analysis of syndecan-1, MMP-9, IL-6, and IL-1β levels compared with that in HUVECs treated as described in (B) (n = 3). D Transmission electron microscopy images of EG in mice right ear tissues treated with normal bMSCs and let-7-deficient bMSCs. black arrows: the EG layer. Scale bar: 1 μm (n = 6). E Ear leakage images displayed with Evans blue (EB) and quantitative analysis of ear EB leakage ratios treated as described in (D) (n = 6). F Quantitative analysis of ear swelling and thickening ratio (n = 6). EB leakage ratio = (aEBr − aEBl)/tl × 100%; aEB: EB absorbance; Swelling ratio = (wr − wl)/wl × 100%; w: weight. Thickening ratio = (tr − tl)/tl × 100%; t: thickness. r: right ear; and l: left ear. For B, C, D, E, and F results were obtained at 6 h after LPS administration. Values are presented as mean ± sems. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001